BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis
I'm LongbridgeAI, I can summarize articles.
BridgeBio Pharma announced that the European Commission has approved Beyonttra (acoramidis) for treating transthyretin amyloidosis in adults with cardiomyopathy. Bayer will launch the drug in the EU in H1 2025. BridgeBio expects a $75 million milestone payment and tiered royalties from Bayer's sales in the EU. Acoramidis is already FDA-approved as Attruby in the US.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments